| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 79 |
| 1 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 75 |
| 2 | TACROLIMUS OINTMENT 0.1% | 75 |
| 3 | MYCOPHENOLATE MOFETIL | 66 |
| 4 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 66 |
| 5 | METHYLPREDNISOLONE | 54 |
| 6 | PREDNISONE | 51 |
| 7 | VORICONAZOLE | 47 |
| 8 | VORICONAZOLE INJECTION | 47 |
| 9 | CYCLOPHOSPHAMIDE | 40 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CASPOFUNGIN ACETATE | 34 | 0.0214 |
| 1 | DAUNORUBICIN HYDROCHLORIDE | 16 | 0.0097 |
| 2 | MILTEFOSINE | 2 | 0.0052 |
| 3 | AMPHOTERICIN B | 31 | 0.0024 |
| 4 | FLUCYTOSINE | 3 | 0.0021 |
| 5 | ANIDULAFUNGIN | 3 | 0.0018 |
| 6 | VORICONAZOLE | 47 | 0.0015 |
| 7 | AMPHOTERICIN B LIPOSOME | 3 | 0.0013 |
| 8 | POSACONAZOLE | 21 | 0.0013 |
| 9 | MICAFUNGIN SODIUM | 8 | 0.0012 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 121 |
| 1 | Azole Antifungal [EPC] | 61 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 42 |
| 3 | Alkylating Drug [EPC] | 41 |
| 4 | Topoisomerase Inhibitor [EPC] | 38 |
| 5 | Kinase Inhibitor [EPC] | 37 |
| 6 | Polyene Antifungal [EPC] | 36 |
| 7 | Lipid-based Polyene Antifungal [EPC] | 34 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 31 |
| 9 | Calcineurin Inhibitor Immunosuppressant [EPC] | 17 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Antileishmanial [EPC] | 2 | 0.0052 |
| 1 | Lipid-based Polyene Antifungal [EPC] | 34 | 0.0026 |
| 2 | Nucleoside Analog Antifungal [EPC] | 3 | 0.0021 |
| 3 | Echinocandin Antifungal [EPC] | 10 | 0.0012 |
| 4 | Selective T Cell Costimulation Blocker [EPC] | 5 | 0.0011 |
| 5 | Polyene Antifungal [EPC] | 36 | 0.0009 |
| 6 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 16 | 0.0007 |
| 7 | Hematopoietic Stem Cell Mobilizer [EPC] | 1 | 0.0007 |
| 8 | Antimetabolite Immunosuppressant [EPC] | 13 | 0.0006 |
| 9 | Topoisomerase Inhibitor [EPC] | 38 | 0.0005 |